Emerging therapies for the prevention and treatment of oral mucositis

Expert Opinion on Emerging Drugs

Volumn 19, Issue 3, 2014, Pages 343-351

  Yuan, Anna ^b   Sonis, Stephen ^a  

^a Biomodels   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemotherapy; Mucositis; Prevention; Radiation; Risk prediction; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; KERATINOCYTE GROWTH FACTOR;

ANIMAL; DRUG APPROVAL; DRUG DESIGN; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; STEM CELL TRANSPLANTATION; STOMATITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG DESIGN; FIBROBLAST GROWTH FACTOR 7; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; STEM CELL TRANSPLANTATION; STOMATITIS;

EID: 84906816647     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.946403     Document Type: Review

References (26)

1. Carlotto A, Hogsett V, Mairorini EM, et al. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics 2013;31:753-66
2. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
3. Sonis ST. Mucositis as a biologic process. A new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998;34:39-43
4. Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time. Gynecol Oncol 2002;87:118-28
5. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009;45:1015-20
6. Sivendran S, Latif A, McBride RB, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol 2014;32:83-9
7. Bowen JM, Elad S, Hutchins RD, et al. Methodology for the MASCC/ISOO mucositis clinical practice guidelines update. Support Care Cancer 2010;1:303-8
8. Bensinger W, Schubert M, Ang KK, et al. NCCN task force report. Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008(Suppl 1):S1-21
9. Spielberger P, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8
10. Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebocontrolled clinical trial. Cancer 2001;92:875-85
11. Nicolatou-Galitis O, Sacci T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 2013;21:357-64
12. Allison RR, Ambrad AA, Arshoun Y, et al. Multi-institutional, randomized, double-blind, placbo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (Mugard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer 2014;120(9):1433-40
13. Bushsel PC. Polyvinylpyrrolidone-sodium hyaluronate gel (GelClair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin Drug Metab Toxicol 2008;4:1449-54
14. Quinn B. Efficacy of a supersaturated calcium phosphate oral rinse for the penetration and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data. Eur J Cancer Care(Engl) 2013;22:564-79
15. Raphael MF, den Boer AM, Kollen WJ, et al. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Support Care Cancer 2014;22:3-6
16. Dodd MJ, Dibble SC, Miaskowski C, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapyinduced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:39-47
17. Clarkson SE, Worthington HV, Furness S, et al. Intervention for treating oral mucositis for patients receiving cancer treatment. Cochrane Database Syst Rev 2010(8):CD001973
18. Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical oral G-CSF on oral mucositis: a randomized placebocontrolled trial. Bone Marrow Transplant 1998;22:781-5
19. Hoffman KE, Pugh SL, Scarantino C, et al. The impact of concurrent granulocyte-macrophage colony stimulating factor on quality of life in head and neck cancer patients: results of the placebo-controlled Radiation Therapy Oncology Group 9901 Trial. Qual Life Res 2014;23(6):1841-58
20. Han G, Bian L, Cotrim A, et al. Preventive and therapeutic effect of Smad7 on radiation-induced oral mucositis. Nat Med 2013;194:21-8
21. Nomura M, Kamata M, Kojima H. Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy oral mucositis. Ann Oncol 2013;24:1062-6
22. Limaye SA, Haddad RI, Cilli F, et al. Phase 1b, Multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 2013;119(24):4268-76
23. Sonis ST. Can oral glutamine prevent mucositis in children undergoing stemcell transplantation? Nat Clin Pract Oncol 2006;3:244-5
24. Sonis ST, Antin JA, Tedaldi MW, et al. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 2013;19:721-7
25. Wygoda A, Maciejewski B, Skladowski K, et al. Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated radiation. Int J Radiat Oncol Biol Phys 2009;73:384-90
26. Alterovitz G, Tuthill C, Rios I, et al. Personalized medicine for mucositis: bayesian networks identify unique gene clusters which predict the response to gamma-D-glutamyl-Ltryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis. Oral Oncol 2011;47:951-5